Pfizer obtained Neurontin in its 2000 acquisition of Warner Lambert Corp.ĭue to the earlier settlement, Pfizer’s marketing practices have been under federal supervision for the past five years. In the 2004 case, Pfizer agreed to pay $430 million to federal and state governments and pleaded guilty to criminal charges of illegally marketing epilepsy drug Neurontin for migraine headaches, pain and bipolar disorder. Kopchinski’s share was expected to be more than $51.5 million. Six whistleblowers, including John Kopchinski, a former sales representative who exposed Pfizer’s Bextra marketing tactics, sparking the government probes, will be rewarded with more than $102 million under the False Claims Act. Pfizer said it will pay $503 million to resolve practices involving Bextra, $301 million related to its schizophrenia drug Geodon, $98 million for Zyvox and about $50 million for its blockbuster Lyrica used to treat nerve pain and seizures. The settlement is the largest to date for improper marketing of prescription drugs, topping the $1.42 billion Eli Lilly and Co agreed to pay earlier this year for off-label sales of its Zyprexa schizophrenia drug. That would have put Pfizer out of business.”
#PLAY DATE GREED CORP TRIAL#
If it had fought the government at trial and lost, and a judge imposed a criminal sentence, that could have resulted in a corporate death penalty. Sandra Jordan, a former federal prosecutor and professor at the Charlotte School of Law in North Carolina, said: “Pfizer can survive this and pay the money. “However, it could send the wrong message at a time when you’re making some pretty critical negotiations with the U.S.
The settlement and guilty plea are not expected to significantly hurt Pfizer’s ability to sell drugs, Morningstar analyst Damien Conover said. Justice Department officials said cracking down on fraud in the healthcare industry was a key priority and comes as President Barack Obama is trying to push through reforms of the $2.5 trillion healthcare system to clip soaring costs. “We regret certain actions taken in the past, but are proud of the action we’ve taken to strengthen our internal controls,” said Amy Schulman, Pfizer’s general counsel. Pfizer denied all of the civil allegations, except for acknowledging improper promotions of the antibiotic Zyvox. Food and Drug Administration - and payments to healthcare professionals. The settlement also includes $1 billion in civil payments related to so-called “off-label” sales of drugs - meaning for uses not authorized by the U.S. The company and Pharmacia also used advisory boards, consultant meetings and provided travel to lavish resorts to improperly promote Bextra to doctors and made misleading claims about the drug’s safety and efficacy, the government said. Pfizer may pay $525 million for Brazil drugmaker: report
0 kommentar(er)
